Author: Dr Burrinder Grewal, Director – pharma and healthcare, LSE Enterprise
Drawing on academic experts from LSE, the company has begun work on a multi-year project with a leading global pharmaceutical company that is developing a new therapy in the area of gastrointestinal medicine. The cell-based therapy involves harvesting cells from a patient and then implanting them at a different site of their body. The therapy is currently progressing through clinical trials.
The regulatory and reimbursement approval frameworks for such a novel product are not fixed but are evolving across countries. Researchers at LSE are working closely with the pharmaceutical company and agencies across Europe to research and understand existing policy and where this needs to be developed further.
Would you like to find out more about policy in the pharmaceutical area? Contact us using the form below to explore what consultancy or tailored training we can offer.
